Tra­vere inks bile acid di­vesti­ture; Madri­gal com­pletes NASH ap­proval re­quest

Tra­vere Ther­a­peu­tics is of­fload­ing its bile acid prod­ucts as Mirum Phar­ma­ceu­ti­cals picks up the rare liv­er dis­ease as­sets for $210 mil­lion up­front.

Mirum could pay …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER